TRanscriptomic Analysis of Circulating Endothelial Cells During Sepsis - TRACES Study (TRACES)
Dysfunction and Endothelial Repair in Sepsis Shock : RNAseq Transcriptomic Analysis of Circulating Endothelial Cells
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Studietyp
Studietyp
Inskrivning (Förväntat)
Inskrivning
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: Lara Zafrani, MD PhD
- Telefonnummer: +33 1 42 49 94 19
- E-post: lara.zafrani@aphp.fr
Studieorter
-
-
-
Paris, Frankrike, 75010
- AP-HP Hôpital Saint Louis
-
Kontakt:
- Lara Zafrani, MD PhD
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Age between 18 and 85 years
- Admission in intensive care with or without sepsis
- Health insurance as per the national insurance system
- Informed and unopposed patient for participation (or referend closed one)
Exclusion Criteria:
- Patient under legal protection
- Patient under national medical help system
- Pregnancy
Studieplan
Hur är studien utformad?
Designdetaljer
Antal grupper/kohorter
Kohorter och interventioner
Grupp / KohortGrupp / Kohort |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Critically ill patients with sepsis
|
Observational study.
Groups are defined based on baseline patients' characteristics : presence or absence of sepsis.
|
|
Critically ill patients without sepsis
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Gene expression based on transcriptom analysis of circulating endothelial cells
Tidsram: Day 1
|
Gene expression based on transcriptom analysis of circulating endothelial cells (RNAseq)
|
Day 1
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Counts of circulating endothelial cells
Tidsram: Day 1 and Day 3
|
Counts of circulating endothelial cells, including progenitor cells
|
Day 1 and Day 3
|
|
Sequential Organ Failure Assessment (SOFA) score
Tidsram: Day 1, Day 3, Day 7
|
Sequential Organ Failure Assessment (SOFA) score, ranging from 0 (best: absence of organ failure) to 24 (worse: multiple organ failure)
|
Day 1, Day 3, Day 7
|
|
Sequential Organ Failure Assessment (SOFA) hemodynamic sub-score
Tidsram: Day 1, Day 3, Day 7
|
Sequential Organ Failure Assessment (SOFA) hemodynamic sub-score, ranging from 0 (best: absence of hemodynamic failure) to 4 (worse: hemodynamic failure)
|
Day 1, Day 3, Day 7
|
|
Sequential Organ Failure Assessment (SOFA) respiratory sub-score
Tidsram: Day 1, Day 3, Day 7
|
Sequential Organ Failure Assessment (SOFA) respiratory sub-score, ranging from 0 (best: absence of respiratory failure) to 4 (worse: respiratory failure)
|
Day 1, Day 3, Day 7
|
|
Sequential Organ Failure Assessment (SOFA) neurological sub-score
Tidsram: Day 1, Day 3, Day 7
|
Sequential Organ Failure Assessment (SOFA) neurological sub-score, ranging from 0 (best: absence of neurological failure) to 4 (worse: neurological failure)
|
Day 1, Day 3, Day 7
|
|
Sequential Organ Failure Assessment (SOFA) hematological sub-score
Tidsram: Day 1, Day 3, Day 7
|
Sequential Organ Failure Assessment (SOFA) hematological sub-score, ranging from 0 (best: absence of hematological failure) to 4 (worse: hematological failure)
|
Day 1, Day 3, Day 7
|
|
Intensive care unit (ICU) mortality
Tidsram: ICU length of stay
|
Death during ICU stay
|
ICU length of stay
|
|
D28 mortality
Tidsram: Day 28
|
Death within 28 days of intensive care unit
|
Day 28
|
|
Hospital mortality
Tidsram: Day 90
|
Death within 90 days of intensive care unit
|
Day 90
|
|
Duration of ventilation
Tidsram: Day 28
|
Number of days alive without ventilation up to Day 28
|
Day 28
|
|
Duration of renal replacement therapy (RRT)
Tidsram: Day 28
|
Number of days alive without RRT up to Day 28
|
Day 28
|
|
Duration of vasopressors therapy
Tidsram: Day 28
|
Number of days alive without vasopressors up to Day 28
|
Day 28
|
|
Dose of vasopressors
Tidsram: ICU length of stay, assessed up to 90 days
|
Dose of vasopressors, in patients who received vasopressors
|
ICU length of stay, assessed up to 90 days
|
|
Duration of intensive care unit (ICU) stay
Tidsram: Day 28
|
Number of days alive outside the ICU up to D28
|
Day 28
|
|
Circulating endothelial cells cytokines profile
Tidsram: Day 1 and 3
|
Dosage of cytokines from circulating endothelial cells
|
Day 1 and 3
|
|
Circulating endothelial cells chemokines profile
Tidsram: Day 1 and 3
|
Dosage of chemokines from circulating endothelial cells
|
Day 1 and 3
|
|
Expression of membrane proteins of endothelial cells
Tidsram: Day 1 and 3
|
Expression of membrane proteins of endothelial cells by flow cytometry
|
Day 1 and 3
|
|
Infection site
Tidsram: Day 1
|
Infection site for patients with sepsis
|
Day 1
|
|
Infection identification
Tidsram: Day 1
|
Identified germs for patients with sepsis
|
Day 1
|
|
Number of participants with different types of antibiotic treatment
Tidsram: Length of ICU stay, assessed up to 90 days
|
Antibiotic treatments for patients with sepsis during intensive care unit (ICU) stay
|
Length of ICU stay, assessed up to 90 days
|
Samarbetspartners och utredare
Sponsor
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Förväntat)
Studiestart
Primärt slutförande (Förväntat)
Primärt slutförande
Avslutad studie (Förväntat)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- APHP201060
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .